Current research status and clinical application progress of the immune checkpoint LAG-3 and its target-ing drugs
10.3969/j.issn.1006-5725.2024.11.024
- VernacularTitle:免疫检查点LAG-3及其靶向药物研究现状和临床应用进展
- Author:
Huinan ZHOU
1
,
2
;
Kewei QIN
;
Lijun ZHOU
Author Information
1. 中国人民解放军总医院第六医学中心耳鼻喉头颈外科医学部研究所(北京 100048)
2. 南方医科大学第二临床医学院(广州 510280)
- Keywords:
lymphocyte activation gene 3;
immune checkpoint;
tumor;
therapeutic antibody
- From:
The Journal of Practical Medicine
2024;40(11):1607-1612
- CountryChina
- Language:Chinese
-
Abstract:
Lymphocyte-activation gene 3(LAG-3)is an inhibitory immune checkpoint receptor that negatively regulates the function of T cells to prevent over-activation of the immune system from damaging human body.In the existence of tumors and chronic infections,persistent antigenic stimulation induces upregulation of LAG-3 expression in effector T cells,leading to T cell exhaustion and tumor immune escape.Targeting LAG-3 drugs can reactivate the anti-tumor function of T cells by specifically blocking the signaling pathway of LAG-3,and have shown promising efficacy in a variety of solid tumors,hematologic tumors and autoimmune diseases.In this paper,we summarize the current research progress on the structure,ligand and regulatory function of LAG-3,review the current status of clinical trials of LAG-3-targeted drugs,and further discuss the clinical application strategy and development direction of LAG-3-targeted drugs,with a view to providing reference for further in-depth research on LAG-3.
